share_log

PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine

PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine

PharmaDrug 的 SecureDose 宣佈推進其藥用級可卡因生物合成配方的工藝開發
newsfile ·  04/16 20:44

Victoria's Chiral Labs to lead development of novel cocaine manufacturing process

維多利亞州的Chiral實驗室將領導新型可卡因製造工藝的開發

Toronto, Ontario--(Newsfile Corp. - April 16, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the Company's wholly-owned subsidiary, Securedose Synthetics Inc. ("SecureDose") has engaged Victoria-based Chiral Logistics Corp. ("Chiral Labs")  to advance and refine practical process development for SecureDose's provisionally patented novel Cocaine synthesis method. Processes developed by Chiral Labs for SecureDose will be the wholly owned intellectual property of SecureDose.

安大略省多倫多--(Newsfile Corp.,2024年4月16日)——專注於受控物質、天然藥物和先前批准藥物研究、開發和商業化的專業製藥公司PharmaDrug Inc.(CSE:PHRX)(OTC Pink:LMLF)(“PHarmaDrug” 或 “公司”)欣然宣佈,該公司的全資子公司Securedose Synthetics Inc..(“SecureDose”)已聘請總部位於維多利亞州的Chiral Logistics Corp.(“Chiral Labs”)來推進和完善SecureDose臨時獲得專利的實際工藝開發新的可卡因合成方法。Chiral Labs爲SecureDose開發的流程將是SecureDose的全資知識產權。

Chiral Labs is a contract research laboratory specializing in chemical synthesis and process optimization in the pharmaceutical and natural science domains. Chiral Labs's Health Canada issued controlled substances licence allows them to work with a wide range of regulated compounds and a recent amendment to expand the licence to accommodate this research has been submitted for approval to Health Canada.

Chiral Labs是一家合同研究實驗室,專門從事製藥和自然科學領域的化學合成和工藝優化。Chiral Labs的加拿大衛生部頒發的受控物質許可證允許他們使用各種受管制的化合物,最近一項擴大許可證範圍以適應這項研究的修正案已提交加拿大衛生部批准。

Robert Steen, CEO of PharmaDrug commented, "We are extremely excited to begin working with Chiral Labs. The work will focus on both fine tuning the process and producing a test batch to prove out our method and formulation. We will also seek to partner with a licensed contract commercial manufacturer to collaborate on tactical commercial methods with a goal to begin producing a larger commercial batch early next year."

PharmaDrug首席執行官羅伯特·斯蒂恩評論說:“我們非常高興開始與Chiral Labs合作。這項工作將側重於微調工藝,並生產一批測試以證明我們的方法和配方。我們還將尋求與一家獲得許可的合同商業製造商合作,就戰術商業方法進行合作,目標是在明年初開始生產更大的商用批次。”

The agreement was signed by both parties on April 8, 2024 and the terms of the contract agree to a fee rate of CAD 60,000 per month plus applicable taxes. A CAD 50,000 plus applicable taxes deposit was already paid against the first month. The project is anticipated to be completed in seven to nine months.

該協議於2024年4月8日由雙方簽署,合同條款約定每月6萬加元的費用率加上適用的稅費。第一個月已經支付了50,000加元外加適用的稅款按金。該項目預計將在七到九個月內完成。

The SecureDose Pharmaceutical Cocaine Project

SecureDose 藥用可卡因項目

SecureDose initiated work in 2023 on a project to develop a novel manufacturing method for the commercial-scale manufacture of cocaine to support safe supply programs. PharmaDrug has already filed a patent for a novel method of development utilizing biosynthetic chemistry (see press release dated March 13, 2024), which it believes will allow for cost effective and efficient Good Manufacturing Practice ("GMP") manufacturing of pharmaceutical grade cocaine at scale.

SecureDose於2023年啓動了一個項目,該項目旨在開發一種用於商業規模製造可卡因的新型製造方法,以支持安全供應計劃。PharmaDrug已經申請了一種利用生物合成化學的新型開發方法的專利(見2024年3月13日的新聞稿),它認爲這將允許大規模生產藥品級可卡因具有成本效益和高效的良好生產規範(“GMP”)。

PharmaDrug's innovative biosynthetic method aims to address these challenges by providing a reliable, clinically manufactured drug product for safe supply programs, potentially transforming the supply chain and offering new revenue or royalty stream opportunities through global partnerships and out-licensing.

PharmaDrug的創新生物合成方法旨在通過爲安全供應計劃提供可靠的臨床製造藥品來應對這些挑戰,有可能改變供應鏈,並通過全球合作伙伴關係和外包許可提供新的收入或特許權使用費流機會。

The Company is dedicated to contributing to harm reduction and believes in a multi-dimensional approach to drug abuse, emphasizing the importance of biosynthetic versions of substances for a regulated pharmaceutical supply chain. PharmaDrug does not condone the abuse of drugs and the Company believes that rehabilitation should continue to be the main focus. However, drug abuse is a complex issue and rehabilitation is not always immediate or achievable for all victims in the short to mid-term. A significant portion of street drugs are contaminated with lethal substances like fentanyl and the supply chain cannot be controlled. Harm reduction for abusers should also be addressed. The Company believes that the only viable way to produce safe supply is to develop biosynthetic versions of these substances to be manufactured domestically in a regulated and pharmaceutical supply chain. The process being developed by PharmaDrug could potentially allow for the cost effective and efficient production of cocaine as a pharmaceutical-grade drug in a variety of facilities and at fairly low cost.

該公司致力於爲減少危害做出貢獻,並相信對藥物濫用採取多維方法,強調生物合成版本的物質對受監管的藥品供應鏈的重要性。PharmaDrug不容忍藥物濫用,該公司認爲康復應繼續是主要重點。但是,藥物濫用是一個複雜的問題,在短期至中期內,並非所有受害者都能立即康復,也無法實現康復。很大一部分街頭毒品受到芬太尼等致命物質污染,供應鏈無法控制。還應解決減少施暴者傷害的問題。該公司認爲,生產安全供應的唯一可行方法是開發這些物質的生物合成版本,在受監管的藥品供應鏈中在國內生產。PharmaDrug正在開發的工藝有可能使可卡因作爲醫藥級藥物在各種設施中以相當低的成本生產具有成本效益和高效率。

Options Grant

期權補助

The Company granted 1.2 million options to a consultant on April 12, 2024. The options can be exercised at a strike price of 5 cents per PharmaDrug share for a period of two years from granting.  

該公司於2024年4月12日向一位顧問授予了120萬份期權。期權可以在授予後的兩年內按每股PharmaDrug股票5美分的行使價。

About PharmaDrug Inc.

關於 PharmaDrug Inc.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs. PharmaDrug owns 51% of Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. PharmaDrug also owns 100% of SecureDose Synthetics Inc. ("SecureDose"), a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution.

PharmaDrug是一家專業製藥公司,專注於受控物質和天然藥物(例如迷幻藥和先前批准的藥物)的研究、開發和商業化。PharmaDrug擁有Sairiyo Therapeutics(“Sairiyo”)51%的股份,Sairiyo Therapeutics(“Sairiyo”)是一家專門研究和重建成熟天然藥物的生物技術公司,其目標是在美國和歐洲通過臨床試驗和相關的監管批准程序。Sairiyo目前正在開發頭孢黃鹼的專利重組配方,該藥物已顯示出相當大的經第三方驗證的治療傳染病和罕見癌症的潛力。Sairiyo還在迷幻藥領域進行研發,用於治療非神經精神疾病。PharmaDrug還擁有SecureDose Synthetics Inc.(“SecureDose”)的100%股份,該公司是一家藥物研發公司,專注於開發當前現有藥物的合成配方,以進行潛在的商業化和分銷。

For further information, please contact:

欲了解更多信息,請聯繫:

Robert J. Steen, Chairman and CEO
rob@pharmadrug.ca
(416) 400-7086

羅伯特·斯蒂恩,董事長兼首席執行官
rob@pharmadrug.ca
(416) 400-7086

Caution Regarding Forward-Looking Information:

關於前瞻性信息的注意事項:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大證券交易所尚未審查本新聞稿的充分性或準確性,也不承擔任何責任。

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Forward looking statements in this press release relate to the ability to develop a novel manufacturing method for the commercial-scale manufacture of cocaine and the timing thereof, the ability to obtain the patent referenced herein,  and the development of the Company's business. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.

本新聞稿可能包含基於當前預期的前瞻性陳述和信息。這些陳述不應被視爲對公司未來業績或業績的保證。本新聞稿中的前瞻性聲明涉及開發用於商業規模製造可卡因的新型製造方法的能力及其時機、獲得此處提及的專利的能力以及公司業務的發展。此類陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際結果、業績或成就與此類陳述所暗示的有重大差異。

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals..

前瞻性信息受已知和未知的風險、不確定性和其他因素的影響,這些因素可能導致公司的實際業績、活動水平、業績或成就與此類前瞻性信息所表達或暗示的結果存在重大差異。此類風險和其他因素可能包括但不限於:一般業務、經濟、競爭、政治和社會的不確定性;一般資本市場狀況和證券市場價格;公司未來經營的實際業績;競爭;影響公司的立法變化;獲得和維持所需許可證和批准的能力、以可接受的條件獲得外部融資的時間和可用性;缺乏合格的熟練勞動力或關鍵人物的流失。

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR+ website at . Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

可能導致實際業績與前瞻性信息存在重大差異的其他風險因素的描述可在SEDAR+網站上公司的披露文件中找到,網址爲。儘管公司試圖確定可能導致實際業績與前瞻性信息中包含的結果存在重大差異的重要因素,但可能還有其他因素導致業績與預期、估計或預期的結果不符。因此,讀者不應過分依賴前瞻性信息。提醒讀者,上述因素清單並不詳盡。進一步提醒讀者不要過分依賴前瞻性信息,因爲無法保證前瞻性信息所依據的計劃、意圖或期望會實現。儘管管理層在編制時認爲此類信息是合理的,但可能被證明是不正確的,實際結果可能與預期結果存在重大差異。

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

公司的證券未根據經修訂的1933年《美國證券法》(“美國證券法”)或適用的州證券法進行註冊,未經註冊或未獲得此類註冊要求的適用豁免,不得向美國個人或 “美國個人”(該術語的定義見《美國證券法案》)或適用的州證券法進行發行或出售,或爲其賬戶或利益。本新聞稿不構成出售要約或徵求買入要約,也不得在美國或任何將此類要約、招攬或出售爲非法的司法管轄區出售證券。

Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

本警示聲明明確限制了本新聞稿中包含的前瞻性信息。本新聞稿中包含的前瞻性信息代表了公司截至本新聞稿發佈之日的預期,因此,在該日期之後可能會發生變化。但是,除非適用的證券法明確要求,否則公司明確否認任何更新或修改任何前瞻性信息的意圖或義務,無論是由於新信息、未來事件還是其他原因。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論